Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580281 · ClinicalTrials.gov registry record · NA
Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT00580281: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00580281 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00580281, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The drug that you are taking for your cancer, imatinib (GleevecTM), has recently been shown to have some new types of side effects. In some people, imatinib can affect how bones are made. The purpose of this study is to find out if imatinib is causing these side effects in you. We can check how your bones form by testing your blood and urine. We can also check your bone strength by doing a special X-ray of your bone called bone density (or DEXA scan).
Interventions
- OTHER blood test, urine test, and bone density x-ray.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-11 |
| Est. Completion | 2013-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580281
The ClinicalTrials.gov registry entry for NCT00580281 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which blood test, urine test, and bone density x-ray. is the first listed.
NCT00580281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580281 about?
NCT00580281 is a clinical study titled "Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors". The drug that you are taking for your cancer, imatinib (GleevecTM), has recently been shown to have some new types of side effects. In some people, imatinib can affect how bones are made. The purpose of this study is to find out if imatinib is causing these side effects in you. We can check how you...
What is the current status of trial NCT00580281?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2006-11. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00580281?
The interventions under investigation include: blood test, urine test, and bone density x-ray. (OTHER).
Who is sponsoring clinical trial NCT00580281?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.